Biology of metastatic renal cell carcinoma

Journal of Cancer

Volumn 2, Issue 1, 2011, Pages 369-373

  Milella, Michele ^a   Felici, Alessandra ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Angiogenesis; Biology; HIF; mTOR; RCC; Signal transduction

Indexed keywords

FIBROBLAST GROWTH FACTOR; INTERLEUKIN 8; MAMMALIAN TARGET OF RAPAMYCIN; PLACENTAL GROWTH FACTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; DISEASE CONTROL; DRUG MECHANISM; GENETIC DISORDER; HUMAN; KIDNEY CARCINOMA; METASTASIS; MOLECULAR DYNAMICS; MUTATIONAL ANALYSIS; REVIEW;

EID: 84862123012     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.2.369     Document Type: Review

References (20)

1. Rini BI. Many treatment options, one patient. J Clin Oncol. 2009; 27: 3225-34.
2. Linehan WM, Bratslavsky G, Pinto PA, et al. Molecular diagnosis and therapy of kidney cancer. Annu Rev Med. 2010; 61: 329-43.
3. Linehan WM, Pinto PA, Srinivasan R, et al. Identification of the genes for kidney cancer: Opportunity for disease-specific targeted therapeutics. Clin Cancer Res. 2007; 13: 671s-9s.
4. Linehan WM, Pinto PA, Bratslavsky G, et al. Hereditary kidney cancer: unique opportunity for disease-based therapy. Cancer. 2009; 115 (10 suppl): 2252-61.
5. Maher ER. Von Hippel Lindau disease. Curr Mol Med. 2004; 4: 833-42.
6. Henske EP. The genetic basis of kidney cancer: Why is tuberous sclerosis complex often overlooked? Curr Mol Med. 2004; 4: 825-31.
7. Kaelin WG Jr. The von Hippel-Lindau tumor suppressor pro-tein and clear cell renal carcinoma. Clin Cancer Res. 2007; 13: 680s-4s.
8. Yeung RS. Lessons from the Eker rat model: From cage to bed-side. Curr Mol Med. 2004; 4: 799-806.
9. Cook JD, Walker GL. The Eker rat: Establishing a genetic para-digm linking renal cell carcinoma and uterine leiomyoma. Curr Mol Med. 2004; 4: 813-24.
10. Ciuffreda L, Di Sanza C, Cesta Incani U, et al. The mTOR pathway: A new target in cancer therapy. Curr Cancer Drug Targets. 2010; 10: 484-95.
11. Furge KA, Chen J, Koeman J, et al. Detection of DNA copy number changes and oncogenic signaling abnormalities from gene expression data reveals MYC activation in high-grade papillary renal cell carcinoma. Cancer Res. 2007; 67: 3171-6.
12. Lendahl U, Lee KL, Yang H, et al. Generating specificity and diversity in the transcriptional response to hypoxia. Nat Rev Genetics. 2009; 10: 821-32.
13. Rini BI, Atkins MB. Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol. 2009; 10: 992-1000.
14. Rini BI. New strategies in kidney cancer: Therapeutic advances through understanding the molecular basis of response and resistance. Clin Cancer Res. 2010; 16: 1348-54.
15. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008; 8: 592-603.
16. Paez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009; 15: 220-31.
17. Faivre S, Demetri G, Sargent W, et al. Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov. 2007; 6: 734-45.
18. Jones RG, Thompson CB. Tumor suppressors and cell metabo-lism: A recipe for cancer growth. Genes Dev. 2009; 23: 537-48.
19. Noonan DM, De Lerma Barbaro A, Vannini N, et al. Inflammation, inflammatory cells, and angiogenesis: Decisions and indecisions. Cancer Metastasis Rev. 2008; 27: 31-40.
20. Seliger B, Massa C. Rini B, et al. Antitumour and immune-adjuvant activities of protein-tyrosine kinase inhibitors. Trends Mol Med. 2010; 16: 184-92.